Skip to main content

Payer Value Strategy-Patient Access Lead

Payer Value Strategy-Patient Access Lead

Date: Feb 13, 2019

Location: Anderlecht, Brussels, BE

Payer Value Strategy lead for bimekizumab (selected indications)

UCB - Inspired by patients. Driven by science. At UCB, we put our heart, soul and skills into making a difference for people living with severe diseases. We look to transform patients' lives by pushing the boundaries in science and solution development. With us, our talents makes the most of who they are, unlocking innovation and setting new standards for patients.

Everything we do starts with a simple question: "How will this make a difference to the lives of people living with severe diseases?"

And to find the answers, we connect globally with patients and their families living with the physical and social burdens of severe disease. These connections give us new perspectives, drive our innovation, and offer a hope for a new generation of therapies that will help to transform lives.

UCB globally is structured into Patient Value Units (being in charge of driving asset strategy and execution by main therapy areas i.e. Bone, Immunology and Neurology PVUs) and Practices which are in charge of scouting the future and providing cutting edge expertise and methodologies for the PVUs to maximize their impact and supporting them on their execution to create patient value.

Colleagues working in the Marketing and Patient Access Practice usually work with a lead indication/asset and support indication/asset to ensure fluid transition and knowledge share between asset teams driven by asset access needs in their lifecycle.

Incumbent reports into Marketing and Patient Access Practice, payer value strategy team. Incumbent focus will be on bimekizumab due to its multiple indications and strategic importance of the asset to UCB. Incumbent is leading the development and execution of the payer value strategy for bimekizumab in selected indications.

Incumbent works closely and in collaboration with the bimekizumab Access Strategy lead, the health economics and pricing team and the access team of major geographies (US, EU5, China, Japan).

The bimekizumab Access Strategy lead is accountable for determining access objectives, insight-driven access strategy, holistic Payer Value Proposition, negotiation strategy, leveraging the portfolio advantage and UCB launch readiness.

The incumbent of the role as payer value strategy lead - patient access will focus on:

1. Preparation of payer value strategy and value proposition

Utilizes the UCB developed patient value framework to quantify the patient value bimekizumab provides in co-creation with health economic and pricing team
* Represents payer needs in cross-functional team activities i.e. clinical development, regulatory, commercial and planning processes i.e. Target Patient Value Profile (aka TPP) development, communications and medical affairs/HCP engagement, payer education/ disease awareness, 10 year planning, patient value brand plan (aka budget plan)
* Ensures that the clinical evidence generation plan from Ph2 till RWE/post-marketing is optimized for payer value strategy, doing this in collaboration with Health Economics, Outcomes Research and Patient-Reported Outcomes colleagues
* Evaluates a broad range of evidence types for their value in contributing to an impactful value story (i.e. patient preference, qualitative researches, RWE beyond the obvious), ensures effective utilization of the totality of available evidence in a timely manner for maximum impact
* Listens and collects actionable insights in a systematic way from key (payer) stakeholders, decision makers, market and competitors, trends and news shared by UCB affiliates. Flexible, quick and adaptive to shape the value proposition and access strategy to reflect trends, competitor landscape and market evolution
* Seeks input and alignment with key internal stakeholders, including major geographies, Bimekizumab Access Strategy Lead, Immunology Real World Evidence Team, etc

1. Development of payer value strategy and value proposition

* Co-develops the expanded payer value proposition of Bimab in selected indications taking into account the traditional (clinical differentiation, safety profile, economic value) and new value drivers (patient experience, social/legal/caregiver aspects) as well as the additional 'beyond-the-drug' offerings UCB might develop to support patients and the system to overcome identified break points through the patient/treatment journey
* Co-develops Bimekizumab Access Strategy in selected indications which maximizes the impact of the value proposition tailored for payer archetypes with specific focus on major geographies needs (i.e. EU5, US, Japan, China)
* The strategy should be aligned with the broader bimekizumab asset strategy and UCB Immunology portfolio strategy
* Champions the payer value strategy with internal stakeholders (BKZ Market-Facing Team, Development Team, HEOR colleagues, PRO colleagues, RWE colleagues)
* Collaborates with the Publications Lead and Access Lead to ensure that payer needs for publications are met and that publications in the plan are optimized for payers

1. Bring outside in

* Leads efforts to ensure payer input and external validation of critical assumptions and plans associated with payer strategy for chances of successful negotiations are elevated
* Leads activities to externally and internally validate and critique clinical development program and Payer Value Strategy plans, using multiple approaches (advisory boards, market research, ad hoc interactions) to maximize the asset strategy and available data-set by launch
* Develops collaborations with payers, policy makers and consultants to improve UCB's Payer value strategies and plans
* Collaborates with major geographies in pre-approval interactions with payers and making connections to the broader development team for effective, efficient and insightful early advice meetings
* Builds on learning from Immunology Patient Value Unit; considers ways in which past or ongoing activities for Cimzia and non-drug solutions could be leveraged; contributes to the development of an Immunology access strategy (considering existing and future portfolio)

1. Development of core global value materials

* Delivers payer value story related global materials i.e. global value dossier, value proposition slide deck, access strategy implementation guide, Q&A/objection handler, video/podcast presentations, other customer-facing materials for payers, etc and being critical and innovative in mindset on how these materials can be improved further to meet UCB affiliates' and payers' needs
* Develops negotiation strategy based on patient value, including outcomes-based / innovative agreements, financing models where these can bring value

1. Supports local implementation of global access strategy

* Excellence in launch execution: leads knowledge transfer of strategy and tactics from Global to affiliates and supports effective preparation and implementation of access strategies in major geographies (as per UCB's pricing and reimbursement submission guidance)
* Develops and implements value story and access strategy related trainings (i.e. launch readiness, launch implementation trainings, payer MOCK sessions) for local access teams

Incumbent profile:

Education
* Educated to a Bachelors level, in a relevant life sciences or business-related discipline
* Specific qualifications such as Health Economics, HTA, or Public Health, Masters or PhD (optional, but preferred)
Experience
* Minimum 6 years of experience in market access-related functions in the (bio)pharmaceutical industry or consulting, could include: health economics, outcomes research, or health technology assessment
* Proven expertise in US Health Care Ecosystem environment
* Expertise in the European Health Care Ecosystem
* At least 3 years of experience in a global oversight role in the development of access strategy and/or payer evidence
* Proven track record in the design and implementation of global access strategies, payer and HTA submissions/interactions and/or payer insights generation
* Product launch experience
* Demonstration of successful working relationships with external stakeholders / KOLs
* Therapeutic area experience in Immunology (optional)
Required Skills - General
* Excellent interpersonal and leadership skills
* Payer access strategy excellence with knowledge of key approaches, critical steps
* Technical ability to lead and deliver projects relevant to the functional objectives
* Strong understanding of needs of payers and strategies for success in market access
* Strong project planning and management skills
* Excellent communication skills with individuals with different cultural, professional and academic backgrounds, including the ability to simplify complex issues
* Builds actively on long-term relationships, both internally and externally across different functions
* Strategic thinking, problem-solving ability, customer focus, and commitment to quality
Specific Skills / Behaviors
* Team player, collaborative balanced with a bias for fast decision making
* Proactive & results driven
* Positive, can-do attitude
* Self-confident, good at influencing
* Scientifically inquisitive
* Ability to lead cross-functional meetings and projects across matrix and geographies
* Excellent command of written and spoken English
* Strong understanding of principles of good scientific and commercial communication and clear messaging to enable ease of understanding by target audiences
* Enjoys to work in cross-functional, matrix environment, being energized by co-developing strategies and materials within team, endures ambiguity, frequent changes in team set-up and organizational surrounding
Location: US ( Atlanta); UK; or Belgium

Job Segment: Neurology, Medical, Immunology, Consulting, Law, Healthcare, Technology, Legal

Payer Value Strategy-Patient Access Lead

UCB, Anderlecht
Contract Type: 
Permanent contract
Categories: 
Manager